Onderneming Clarus Therapeutics Holdings, Inc.
Aandelen
CRXT
US18271L1070
Farmaceutische producten
Vakgebied
Aantal werknemers: 16
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Robert Dudley
FOU | Founder | 69 | 01-01-04 |
Jay Newmark
CTO | Chief Tech/Sci/R&D Officer | - | - |
Kara Stancell
IRC | Investor Relations Contact | - | - |
Sales & Marketing | - | 01-03-20 | |
Corporate Officer/Principal | - | 17-01-22 | |
James Holloway
PRN | Corporate Officer/Principal | - | - |
Lawrence Perkins
PRN | Corporate Officer/Principal | 47 | - |
Mike Cleveland
SAM | Sales & Marketing | - | 01-02-22 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Dudley
FOU | Founder | 69 | 01-01-04 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 52 020 731 | 50 674 645 ( 97,41 %) | 0 | 97,41 % |
Bedrijfsgegevens
Clarus Therapeutics Holdings, Inc.
355 South Grand Avenue Suite 1450
90071, Los Angeles
+
http://clarustherapeutics.comSector
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,46% | 659 mld. | |
+25,80% | 557 mld. | |
-4,86% | 359 mld. | |
+16,44% | 322 mld. | |
+8,34% | 297 mld. | |
+6,32% | 215 mld. | |
+7,60% | 210 mld. | |
-6,26% | 200 mld. | |
-8,79% | 149 mld. |